Pharmacogenetic Optimization of Smoking Cessation Treatment

Trends in Pharmacological Sciences

Volumn 38, Issue 1, 2017, Pages 55-66

  Chenoweth, Meghan J ^a,b   Tyndale, Rachel F ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

metabolism; nicotine; pharmacogenetics; smoking cessation; tobacco; treatment

Indexed keywords

AMFEBUTAMONE; CYTOCHROME P450 2A6; ORGANIC CATION TRANSPORTER 2; VARENICLINE; CYP2A6 PROTEIN, HUMAN; CYP2B6 PROTEIN, HUMAN; CYTOCHROME P450 2B6; DOPAMINE 4 RECEPTOR; NICOTINE; NICOTINIC RECEPTOR; ORGANIC CATION TRANSPORTER; SLC22A2 PROTEIN, HUMAN;

CHRNA5 GENE; CHRNB4 GENE; DOPAMINERGIC SYSTEM; DRUG EFFICACY; GENE; GENE CLUSTER; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIATION; HELP SEEKING BEHAVIOR; HEREDITY; HUMAN; NACHR GENE; OUTCOME ASSESSMENT; PHARMACOGENETICS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVIEW; SMOKING CESSATION; GENETICS; METABOLISM; PROCEDURES; SINGLE NUCLEOTIDE POLYMORPHISM;

CYTOCHROME P-450 CYP2A6; CYTOCHROME P-450 CYP2B6; GENETIC VARIATION; HUMANS; NICOTINE; ORGANIC CATION TRANSPORT PROTEINS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, DOPAMINE D4; RECEPTORS, NICOTINIC; SMOKING CESSATION;

EID: 85000919199     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2016.09.006     Document Type: Review

References (81)

1. 1 Henningfield, J.E., Nicotine medications for smoking cessation. N. Engl. J. Med. 333 (1995), 1196–1203.
2. 2 Hurt, R.D., et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl. J. Med. 337 (1997), 1195–1202.
3. 3 Faessel, H.M., et al. A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clin. Pharmacokinet. 49 (2010), 799–816.
4. 4 Learned-Coughlin, S.M., et al. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol. Psychiatry 54 (2003), 800–805.
5. 5 Broms, U., et al. Genetic architecture of smoking behavior: a study of Finnish adult twins. Twin Res. Hum. Genet. 9 (2006), 64–72.
6. 6 Pianezza, M.L., et al. Nicotine metabolism defect reduces smoking. Nature, 393, 1998, 750.
7. 7 Leung, T., et al. Effect of the rs1051730-rs16969968 variant and smoking cessation treatment: a meta-analysis. Pharmacogenomics 16 (2015), 713–720.
8. 8 Chen, L.S., et al. CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis–a meta-analysis. J. Natl. Cancer Inst., 107, 2015, djv100.
9. 9 Benowitz, N.L., Nicotine addiction. N. Engl. J. Med. 362 (2010), 2295–2303.
10. 10 Nakajima, M., et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab. Dispos. 24 (1996), 1212–1217.
11. 11 Al Koudsi, N., Tyndale, R.F., Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism. Xenobiotica 40 (2010), 381–392.
12. 12 Benowitz, N.L., et al. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb. Exp. Pharmacol., 2009, 29–60.
13. 13 Nakajima, M., et al. Characterization of CYP2A6 involved in 3’-hydroxylation of cotinine in human liver microsomes. J. Pharmacol. Exp. Ther. 277 (1996), 1010–1015.
14. 14 Dempsey, D., et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin. Pharmacol. Ther. 76 (2004), 64–72.
15. 15 Tanner, J.A., et al. Nicotine metabolite ratio (3-hydroxycotinine/cotinine) in plasma and urine by different analytical methods and laboratories: implications for clinical implementation. Cancer Epidemiol. Biomarkers Prev. 24 (2015), 1239–1246.
16. 16 Lea, R.A., et al. Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate. J. Anal. Toxicol. 30 (2006), 386–389.
17. 17 Mooney, M.E., et al. Stability of the nicotine metabolite ratio in ad libitum and reducing smokers. Cancer Epidemiol. Biomarkers Prev. 17 (2008), 1396–1400.
18. 18 St Helen, G., et al. Stability of the nicotine metabolite ratio in smokers of progressively reduced nicotine content cigarettes. Nicotine Tob. Res. 15 (2013), 1939–1942.
19. 19 Benowitz, N.L., et al. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin. Pharmacol. Ther. 80 (2006), 457–467.
20. 20 Chenoweth, M.J., et al. Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers. Cancer Epidemiol. Biomarkers Prev. 23 (2014), 1773–1782.
21. 21 Schnoll, R.A., et al. High dose transdermal nicotine for fast metabolizers of nicotine: a proof of concept placebo-controlled trial. Nicotine Tob. Res. 15 (2013), 348–354.
22. 22 Lerman, C., et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Resp. Med. 3 (2015), 131–138.
23. 23 Schoedel, K.A., et al. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14 (2004), 615–626.
24. 24 Wassenaar, C.A., et al. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer Risk. J. Natl. Cancer Inst. 103 (2011), 1342–1346.
25. 25 Sofuoglu, M., et al. Rapid nicotine clearance is associated with greater reward and heart rate increases from intravenous nicotine. Neuropsychopharmacology 37 (2012), 1509–1516.
26. 26 Dubroff, J.G., et al. Decreased nicotinic receptor availability in smokers with slow rates of nicotine metabolism. J. Nucl. Med. 56 (2015), 1724–1729.
27. 27 Tang, D.W., et al. Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI. Neuroimage 60 (2012), 2136–2143.
28. 28 Falcone, M., et al. Brain responses to smoking cues differ based on nicotine metabolism rate. Biol. Psychiatry 80 (2015), 190–197.
29. 29 Gu, D.F., et al. The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann. Hum. Genet. 64 (2000), 383–390.
30. 30 Chenoweth, M.J., et al. CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers. Pharmacogenet. Genom. 23 (2013), 232–235.
31. 31 Patterson, F., et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin. Pharmacol. Ther. 84 (2008), 320–325.
32. 32 Chen, L.S., et al. Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). Addiction 109 (2014), 128–137.
33. 33 Lerman, C., et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin. Pharmacol. Ther. 79 (2006), 600–608.
34. 34 Schnoll, R.A., et al. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol. Biochem. Behav. 92 (2009), 6–11.
35. 35 Lerman, C., et al. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clin. Pharmacol. Ther. 87 (2010), 553–557.
36. 36 Kaufmann, A., et al. Rate of nicotine metabolism and smoking cessation outcomes in a community-based sample of treatment-seeking smokers. Addict. Behav. 51 (2015), 93–99.
37. 37 Kharasch, E.D., et al. Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity. J. Clin. Pharmacol. 48 (2008), 464–474.
38. 38 Rotger, M., et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin. Pharmacol. Ther. 81 (2007), 557–566.
39. 39 Thorn, C.F., et al. PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenet. Genom. 20 (2010), 520–523.
40. 40 Lee, A.M., et al. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol. Psychiatry 62 (2007), 635–641.
41. 41 Zhu, A.Z., et al. CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion. Clin. Pharmacol. Ther. 92 (2012), 771–777.
42. 42 King, D.P., et al. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology 37 (2012), 641–650.
43. 43 Bloom, A.J., et al. CYP2B6 non-coding variation associated with smoking cessation is also associated with differences in allelic expression, splicing, and nicotine metabolism independent of common amino-acid changes. PLoS ONE, 8, 2013, e79700.
44. 44 Garcia, K.L.P., et al. Effect of brain CYP2B inhibition on brain nicotine levels and nicotine self-administration. Neuropsychopharmacology 40 (2015), 1910–1918.
45. 45 Chen, Y., et al. The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19. Xenobiotica 40 (2010), 536–546.
46. 46 Zhu, A.Z., et al. Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes. Drug Metab. Dispos. 42 (2014), 1971–1977.
47. 47 Cahill, K., et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst. Rev., 2013, CD009329.
48. 48 Obach, R.S., et al. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab. Dispos. 34 (2006), 121–130.
49. 49 Feng, B., et al. Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study. Clin. Pharmacol. Ther. 83 (2008), 567–576.
50. 50 Koepsell, H., The SLC22 family with transporters of organic cations, anions and zwitterions. Mol. Aspects Med. 34 (2013), 413–435.
51. 51 Bergen, A.W., et al. Organic cation transporter variation and response to smoking cessation therapies. Nicotine Tob. Res. 16 (2014), 1638–1646.
52. 52 Laviolette, S.R., van der Kooy, D., The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat. Rev. Neurosci. 5 (2004), 55–65.
53. 53 Stead, L.F., et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev., 11, 2012, CD000146.
54. 54 Slemmer, J.E., et al. Bupropion is a nicotinic antagonist. J. Pharmacol. Exp. Therapeut. 295 (2000), 321–327.
55. 55 Coe, J.W., et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. 48 (2005), 3474–3477.
56. 56 Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat. Genet. 42 (2010), 441–447.
57. 57 Chen, L.S., et al. Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. Am. J. Psychiatry 169 (2012), 735–742.
58. 58 Munafo, M.R., et al. Association between genetic variants on chromosome 15q25 locus and objective measures of tobacco exposure. J. Natl. Cancer Inst. 104 (2012), 740–748.
59. 59 Bierut, L.J., et al. Variants in nicotinic receptors and risk for nicotine dependence. Am. J. Psychiatry 165 (2008), 1163–1171.
60. 60 Fowler, C.D., et al. Habenular alpha5 nicotinic receptor subunit signalling controls nicotine intake. Nature 471 (2011), 597–601.
61. 61 Bergen, A.W., et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenet. Genomics 23 (2013), 94–103.
62. 62 Chen, L.S., et al. Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. Drug Alcohol. Depend. 154 (2015), 278–282.
63. 63 Tyndale, R.F., et al. Lack of associations of CHRNA5-A3-B4 genetic variants with smoking cessation treatment outcomes in caucasian smokers despite associations with baseline Smoking. PLoS ONE, 10, 2015, e0128109.
64. 64 Sarginson, J.E., et al. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 156B (2011), 275–284.
65. 65 Zhu, A.Z., et al. Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African-American smokers. Clin. Pharmacol. Ther. 96 (2014), 256–265.
66. 66 Conti, D.V., et al. Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum. Mol. Genet. 17 (2008), 2834–2848.
67. 67 David, S.P., et al. Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. Pharmacogenomics J. 8 (2008), 122–128.
68. 68 Leventhal, A.M., et al. Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation. Pharmacogenomics J. 12 (2012), 86–92.
69. 69 Simpson, J., et al. The DRD4 receptor Exon 3 VNTR and 5’ SNP variants and mRNA expression in human post-mortem brain tissue. Am. J Med. Genet. B. Neuropsychiatr. Genet. 153B (2010), 1228–1233.
70. 70 Bergen, A.W., et al. The DRD4 exon III VNTR, bupropion, and associations with prospective abstinence. Nicotine Tob. Res. 15 (2013), 1190–1200.
71. 71 David, S.P., et al. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob. Res. 9 (2007), 821–833.
72. 72 Jonsson, E.G., et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol. Psychiatry 4 (1999), 290–296.
73. 73 Bjornson, W., et al. Gender differences in smoking cessation after 3 years in the Lung Health Study. Am. J. Public Health 85 (1995), 223–230.
74. 74 Broms, U., et al. Smoking cessation by socioeconomic status and marital status: the contribution of smoking behavior and family background. Nicotine Tob. Res. 6 (2004), 447–455.
75. 75 Trinidad, D.R., et al. A nationwide analysis of US racial/ethnic disparities in smoking behaviors, smoking cessation, and cessation-related factors. Am. J. Public Health 101 (2011), 699–706.
76. 76 David, S.P., et al. Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction 108 (2013), 2202–2211.
77. 77 Wang, J., Li, M.D., Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation. Neuropsychopharmacology 35 (2010), 702–719.
78. 78 Loukola, A., et al. A genome-wide association study of a biomarker of nicotine metabolism. PLoS Genet., 11, 2015, e1005498.
79. 79 Munafo, M.R., et al. CHRNA3 rs1051730 genotype and short-term smoking cessation. Nicotine Tob. Res. 13 (2011), 982–988.
80. 80 De Ruyck, K., et al. Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients. Pharmacogenomics 11 (2010), 1053–1063.
81. 81 De Luca, V., et al. Analysis of nicotinic receptor genes in nicotine replacement treatment. Eur. Psychiatry, 28(Suppl.), 2013, 1.